Solid Biosciences (SLDB) EBITDA (2017 - 2026)
Quarterly results put EBITDA at -$56.8 million for Q1 2026, down 41.82% from a year ago — trailing twelve months through Mar 2026 was -$196.0 million (down 37.11% YoY), and the annual figure for FY2025 was -$179.2 million, down 38.14%.
Solid Biosciences has reported EBITDA over the past 10 years, most recently at -$56.8 million for Q1 2026.
- EBITDA reached -$56.8 million in Q1 2026 per SLDB's latest filing, down from -$49.4 million in the prior quarter.
- Across five years, EBITDA topped out at -$20.5 million in Q3 2022 and bottomed at -$56.8 million in Q1 2026.
- Median EBITDA over the past 5 years was -$30.0 million (2023), compared with a mean of -$33.7 million.
- The largest annual shift saw EBITDA tumbled 85.32% in 2022 before it skyrocketed 35.59% in 2023.
- Over 5 years, EBITDA stood at -$34.6 million in 2022, then surged by 35.59% to -$22.3 million in 2023, then plummeted by 79.19% to -$39.9 million in 2024, then fell by 23.83% to -$49.4 million in 2025, then fell by 14.98% to -$56.8 million in 2026.
- Business Quant data shows EBITDA for SLDB at -$56.8 million in Q1 2026, -$49.4 million in Q4 2025, and -$48.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 661.60 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.82 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | -56.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.80 Mn |
| Dec 31, 2025 | -49.40 Mn |
| Sep 30, 2025 | -48.06 Mn |
| Jun 30, 2025 | -41.69 Mn |
| Mar 31, 2025 | -40.05 Mn |
| Dec 31, 2024 | -39.90 Mn |
| Sep 30, 2024 | -35.18 Mn |
| Jun 30, 2024 | -27.79 Mn |
| Mar 31, 2024 | -26.86 Mn |
| Dec 31, 2023 | -22.27 Mn |
| Sep 30, 2023 | -23.11 Mn |
| Jun 30, 2023 | -26.84 Mn |
| Mar 31, 2023 | -30.00 Mn |
| Dec 31, 2022 | -34.57 Mn |
| Sep 30, 2022 | -20.48 Mn |
| Jun 30, 2022 | -25.16 Mn |
| Mar 31, 2022 | -25.33 Mn |
| Dec 31, 2021 | -18.65 Mn |
| Sep 30, 2021 | -17.99 Mn |
| Jun 30, 2021 | -18.71 Mn |
| Mar 31, 2021 | -16.90 Mn |
| Dec 31, 2020 | -21.36 Mn |
| Sep 30, 2020 | -21.25 Mn |
| Jun 30, 2020 | -18.99 Mn |
| Mar 31, 2020 | -26.70 Mn |
| Dec 31, 2019 | -32.33 Mn |
| Sep 30, 2019 | -29.72 Mn |
| Jun 30, 2019 | -26.97 Mn |
| Mar 31, 2019 | -30.30 Mn |
| Dec 31, 2018 | -22.39 Mn |
| Sep 30, 2018 | -19.15 Mn |
| Jun 30, 2018 | -18.18 Mn |
| Mar 31, 2018 | -15.97 Mn |
| Dec 31, 2017 | -15.16 Mn |
| Sep 30, 2017 | -13.70 Mn |
| Jun 30, 2017 | -11.89 Mn |
| Mar 31, 2017 | -14.11 Mn |